Fuller M A, Tolbert S R
Pharmacy Service, Veterans Affairs Medical Center, Cleveland, OH 44106.
DICP. 1991 Jan;25(1):36-40. doi: 10.1177/106002809102500108.
Parkinson's disease (PD) is a progressive neurologic motor disorder. Currently, levodopa/carbidopa is the standard mode of therapy for PD; however, it does not prevent progression of the disease. Selegiline (also known as deprenyl), is a selective irreversible monoamine oxidase type B inhibitor virtually devoid of the tyramine reaction at the recommended dosage of 10 mg/d. It is approved by the Food and Drug Administration for the adjunctive use in the management of patients with PD who are receiving levodopa/carbidopa and exhibit a "wearing off" effect of levodopa. Numerous clinical trials have been conducted evaluating selegiline's role in the treatment of PD. Preliminary evidence from the DATATOP trial suggests that selegiline may slow the progression of PD when used as initial therapy. However, final results of this trial and additional long-term controlled trials comparing selegiline to levodopa and placebo groups are necessary to further clarify selegiline's role in the treatment of PD.
帕金森病（PD）是一种进行性神经运动障碍。目前，左旋多巴/卡比多巴是治疗帕金森病的标准疗法；然而，它并不能阻止疾病的进展。司来吉兰（也称为丙炔苯丙胺）是一种选择性不可逆的单胺氧化酶B型抑制剂，在推荐剂量10毫克/天时几乎没有酪胺反应。它已被美国食品药品监督管理局批准用于辅助治疗接受左旋多巴/卡比多巴治疗且出现左旋多巴“失效”效应的帕金森病患者。已经进行了许多临床试验来评估司来吉兰在帕金森病治疗中的作用。DATATOP试验的初步证据表明，司来吉兰作为初始治疗使用时可能会减缓帕金森病的进展。然而，需要该试验的最终结果以及将司来吉兰与左旋多巴和安慰剂组进行比较的其他长期对照试验，以进一步阐明司来吉兰在帕金森病治疗中的作用。
